What’s Propelling PETLIFE PHARMACEUTICALS INCORPORATED (OTCMKTS:PTLF) After Lower Shorts Reported?

July 19, 2017 - By Clifton Ray

The stock of PETLIFE PHARMACEUTICALS INCORPORATED (OTCMKTS:PTLF) registered a decrease of 89.02% in short interest. PTLF’s total short interest was 4,600 shares in July as published by FINRA. Its down 89.02% from 41,900 shares, reported previously.

The stock increased 0.56% or $0.001 on July 19, reaching $0.153. About 18,165 shares traded. Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) has 0.00% since July 19, 2016 and is . It has underperformed by 16.70% the S&P500.

PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The company has market cap of $6.85 million. The Firm specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. It currently has negative earnings. The Firm has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula.

More notable recent Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) news were published by: Marketwatch.com which released: “0.149” on September 11, 2014, also Globenewswire.com with their article: “PetLife Pharmaceuticals Rebrands all Products in Preparation for The FDA …” published on August 19, 2016, Globenewswire.com published: “PetLife Pharmaceuticals Provides Positive Update to Shareholders” on October 05, 2015. More interesting news about Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) were released by: Globenewswire.com and their article: “PetLife Pharmaceuticals, Inc. Issues Letter to Shareholders” published on August 16, 2016 as well as Globenewswire.com‘s news article titled: “PetLife Pharmaceuticals reports the First of Three Preclinical Studies in …” with publication date: January 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: